ACTU
Income statement / Annual
Last year (2024), Actuate Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Actuate Therapeutics Inc's net income was -$27.29 M.
See Actuate Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$18.68 M
|
$21.71 M
|
$16.39 M
|
| General & Administrative Expenses |
$6.48 M
|
$3.27 M
|
$3.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.48 M
|
$3.27 M
|
$3.82 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$25.16 M
|
$24.97 M
|
$20.21 M
|
| Cost And Expenses |
$25.16 M
|
$24.97 M
|
$20.21 M
|
| Interest Income |
$222.29 K
|
$352.67 K
|
$27.03 K
|
| Interest Expense |
-$18.72 K
|
$43.64 K
|
$16.20 K
|
| Depreciation & Amortization |
$2.14 M
|
$272.85 K
|
$63.61 K
|
| EBITDA |
-$25.16 M |
-$24.43 M |
-$20.08 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.12 M
|
$229.21 K
|
$47.41 K
|
| Income Before Tax |
-$27.28 M
|
-$24.74 M
|
-$20.16 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$800.00
|
$0.00
|
$0.00
|
| Net Income |
-$27.29 M
|
-$24.74 M
|
-$20.16 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-3.26 |
-1.65 |
-1.34 |
| EPS Diluted |
-3.26 |
-1.65 |
-1.34 |
| Weighted Average Shares Out |
$19.51 M
|
$15.03 M
|
$15.03 M
|
| Weighted Average Shares Out Diluted |
$19.51 M
|
$15.03 M
|
$15.03 M
|
| Link |
|
|
|
